These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31296659)

  • 21. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.
    Pellicci DG; Patel O; Kjer-Nielsen L; Pang SS; Sullivan LC; Kyparissoudis K; Brooks AG; Reid HH; Gras S; Lucet IS; Koh R; Smyth MJ; Mallevaey T; Matsuda JL; Gapin L; McCluskey J; Godfrey DI; Rossjohn J
    Immunity; 2009 Jul; 31(1):47-59. PubMed ID: 19592275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
    Singh AK; Rhost S; Löfbom L; Cardell SL
    Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid.
    Arrenberg P; Halder R; Dai Y; Maricic I; Kumar V
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10984-9. PubMed ID: 20534460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells.
    East JE; Sun W; Webb TJ
    J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells.
    Girardi E; Zajonc DM
    Immunol Rev; 2012 Nov; 250(1):167-79. PubMed ID: 23046129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD1d-Restricted Type II NKT Cells Reactive With Endogenous Hydrophobic Peptides.
    Nishioka Y; Masuda S; Tomaru U; Ishizu A
    Front Immunol; 2018; 9():548. PubMed ID: 29599785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
    Kronenberg M
    J Vis Exp; 2007; (10):635. PubMed ID: 18989407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Turned on by danger: activation of CD1d-restricted invariant natural killer T cells.
    Lawson V
    Immunology; 2012 Sep; 137(1):20-7. PubMed ID: 22734667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model.
    Nambiar J; Clarke AW; Shim D; Mabon D; Tian C; Windloch K; Buhmann C; Corazon B; Lindgren M; Pollard M; Domagala T; Poulton L; Doyle AG
    MAbs; 2015; 7(3):638-50. PubMed ID: 25751125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type II Natural Killer T Cells Contribute to Protection Against Systemic Methicillin-Resistant
    Genardi S; Visvabharathy L; Cao L; Morgun E; Cui Y; Qi C; Chen YH; Gapin L; Berdyshev E; Wang CR
    Front Immunol; 2020; 11():610010. PubMed ID: 33312179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells.
    Venkataswamy MM; Porcelli SA
    Semin Immunol; 2010 Apr; 22(2):68-78. PubMed ID: 19945296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II/T cell receptor interaction results in acute lung injury.
    Rieder SA; Nagarkatti P; Nagarkatti M
    Infect Immun; 2011 Aug; 79(8):3141-8. PubMed ID: 21628519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
    Webb TJ; Bieler JG; Schneck JP; Oelke M
    J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy.
    Joshi SK; Lang GA; Larabee JL; Devera TS; Aye LM; Shah HB; Ballard JD; Lang ML
    PLoS Pathog; 2009 Sep; 5(9):e1000588. PubMed ID: 19779559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unappreciated diversity within the pool of CD1d-restricted T cells.
    Pellicci DG; Uldrich AP
    Semin Cell Dev Biol; 2018 Dec; 84():42-47. PubMed ID: 29183709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of intracellular trafficking of CD1d on the formation of TCR repertoire of NKT cells.
    Shin JH; Park SH
    BMB Rep; 2014 May; 47(5):241-8. PubMed ID: 24755556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.
    Jervis PJ; Polzella P; Wojno J; Jukes JP; Ghadbane H; Garcia Diaz YR; Besra GS; Cerundolo V; Cox LR
    Bioconjug Chem; 2013 Apr; 24(4):586-94. PubMed ID: 23458425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor.
    Patel O; Pellicci DG; Gras S; Sandoval-Romero ML; Uldrich AP; Mallevaey T; Clarke AJ; Le Nours J; Theodossis A; Cardell SL; Gapin L; Godfrey DI; Rossjohn J
    Nat Immunol; 2012 Sep; 13(9):857-63. PubMed ID: 22820603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NKT TCR recognition of CD1d-α-C-galactosylceramide.
    Patel O; Cameron G; Pellicci DG; Liu Z; Byun HS; Beddoe T; McCluskey J; Franck RW; Castaño AR; Harrak Y; Llebaria A; Bittman R; Porcelli SA; Godfrey DI; Rossjohn J
    J Immunol; 2011 Nov; 187(9):4705-13. PubMed ID: 21964029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-talk between cd1d-restricted nkt cells and γδ cells in t regulatory cell response.
    Liu W; Huber SA
    Virol J; 2011 Jan; 8():32. PubMed ID: 21255407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.